This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyazaki, S. Articles by Yamaguchi, K. Search for Related Content PubMed PubMed Citation Articles by Miyazaki, S. Articles by Yamaguchi, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 378-383, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.378-383.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models

Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143-8540, Japan

Received 8 April 2003/ Returned for modification 6 September 2003/ Accepted 4 October 2003

S-3578 is a novel beta-lactam with enhanced activity against drug-resistant gram-positive cocci such as methicillin-resistant Staphylococcus aureus (MRSA). We used murine penicillin-resistant Streptococcus pneumoniae lung infection and neutropenic murine systemic MRSA infection models to determine the pharmacokinetic (PK)-pharmacodynamic (PD) parameter that best correlated with efficacy. Pharmacokinetic studies revealed that the maximum concentration in serum/dose values for S-3578 and cefepime in plasma in the lung infection model were 1.21 to 1.54 and 0.97 to 1.29, respectively; those for S-3578 in plasma in the systemic infection model were 0.78 to 1.02. The area under the concentration-time curve (AUC)/dose values for S-3578 and cefepime in plasma in the lung infection model were 0.98 to 1.13 and 0.77 to 1.04, respectively, and those for S-3578 in plasma in the systemic infection model were 1.03 to 1.11. The half-lives of S-3578 and cefepime in plasma in the lung infection model were 0.29 to 0.38 and 0.29 to 0.34, respectively, and those of S-3578 in plasma in the systemic infection model were 0.40 to 0.61. The time above the MIC was the PK-PD parameter that best correlated with efficacy in the murine lung infection model (R² = 84 and 92% for S-3578 and cefepime in plasma, respectively). There was a twofold increase in the dose of S-3578 in the systemic infection model compared to that in the pneumonia model, yet the AUCs were the same. This may be due to the different MICs for the two pathogens.

This article has been cited by other articles:

• Tam, V. H., Schilling, A. N., Poole, K., Nikolaou, M. (2007). Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60: 1302-1309 [Abstract] [Full Text]  
• Lopez, F. E., Vincent, P. A., Zenoff, A. M., Salomon, R. A., Farias, R. N. (2007). Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J Antimicrob Chemother 59: 676-680 [Abstract] [Full Text]  
• Tam, V. H., Schilling, A. N., Neshat, S., Poole, K., Melnick, D. A., Coyle, E. A. (2005). Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 4920-4927 [Abstract] [Full Text]  
• Tam, V. H., Schilling, A. N., Nikolaou, M. (2005). Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55: 699-706 [Abstract] [Full Text]